Biote Corp (BTMD) FinancialsBTMDBiote Corp

Biote Corp (BTMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Pellet Procedures, accounting for 69.6% of total sales, equivalent to $31.29M. Other significant revenue streams include Dietary Supplements and Disposable Trocars. Understanding this composition is critical for investors evaluating how BTMD navigates market cycles within the Professional Information Services industry.

Evaluating the bottom line, Biote Corp maintains a gross margin of 65.38%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 3.79%, while the net margin is -16.79%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively BTMD converts its operational activities into shareholder value.

In the context of the broader market, BTMD competes directly with industry leaders such as VMD and CYH. With a market capitalization of $40.60M, it holds a significant position in the sector. When comparing efficiency, BTMD's gross margin of 65.38% stands against VMD's 57.19% and CYH's 81.98%. Such benchmarking helps identify whether Biote Corp is trading at a premium or discount relative to its financial performance.

Biote Corp has shown declining revenue, with Q2 2026 revenue reported at $44.2 million, missing expectations of $46.08 million. The company's net income has also turned negative in Q2 2026, with a loss of $6.56 million, compared to a profit of $2.27 million in Q1 2026. Gross margin has decreased from 71.3% in Q4 2024 to 65.38% in Q2 2026, indicating worsening profitability.